However, despite recognizing the importance of FGFR2 mutations in cancers like EC [12,13], the clinical responses to FGFR inhibitors have demonstrated significant variability [14], highlighting the need for a better understanding of which FGFR2 alterations are oncogenic and can be effectively targeted therapeutically. This evidence concerns the gene FGFR2 and cancer.